Evan A. Thackaberry
Corporate Officer/Principal bij VIGIL NEUROSCIENCE, INC.
Vermogen: 3 870 $ op 30-04-2024
Profiel
Evan A.
Thackaberry is currently the Senior Vice President & Head-Early Development at Vigil Neuroscience, Inc. Prior to this, he worked as the Vice President-Non Clinical Development at Ra Pharmaceuticals, Inc. from 2017 to 2020.
Thackaberry holds a doctorate degree from the University of Wisconsin.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
VIGIL NEUROSCIENCE, INC.
0.00% | 01-03-2023 | 1 500 ( 0.00% ) | 3 870 $ | 30-04-2024 |
Actieve functies van Evan A. Thackaberry
| Bedrijven | Functie | Begin |
|---|---|---|
| VIGIL NEUROSCIENCE, INC. | Corporate Officer/Principal | 01-09-2020 |
Eerdere bekende functies van Evan A. Thackaberry
| Bedrijven | Functie | Einde |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-03-2020 |
Opleiding van Evan A. Thackaberry
| University of Wisconsin | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| VIGIL NEUROSCIENCE, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
